Tecarfarin Shows Promise in LVAD Patients with Potential to Improve Anticoagulation
Key Insights
Tecarfarin's data and Cadrenal's trial protocol were presented at the EACTS Mechanical Circulatory Support Summit, focusing on LVAD patients.
Data suggests tecarfarin may improve Time in Therapeutic Range (TTR) and reduce bleeding events compared to warfarin in HM3 LVAD patients.
The TECH-LVAD trial, submitted to the FDA, aims to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 LVAD.
Cadrenal Therapeutics highlighted a presentation at the European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit in November 2024, featuring tecarfarin and its potential in patients with the Abbott HeartMate3 (HM3) left ventricular assist device (LVAD). The presentation, titled Tec arfarin and H emocompatibility with LVAD Therapy (TECH-LVAD), outlined Cadrenal's proposed clinical trial protocol submitted to the FDA.
Dr. Mandeep R. Mehra, from Brigham and Women's Hospital and Harvard University, presented data demonstrating the inverse relationship between bleeding rates and time in therapeutic range (TTR) for HM3 patients. He also highlighted evidence from prior studies suggesting tecarfarin's potential to improve TTR. The data included a trial in end-stage kidney disease (search) (ESKD) patients, showing that ESKD does not alter tecarfarin exposure, unlike warfarin, which sees increased exposure. This is a critical differentiator, as many LVAD patients have kidney impairment.
TECH-LVAD Trial Design
The proposed TECH-LVAD trial aims to study tecarfarin as a VKA option to reduce bleeding events associated with HM3 LVAD use in advanced heart failure (search). According to Dr. Mehra, tecarfarin could be an important therapy for LVAD patients requiring chronic anticoagulation.
Clinical Significance
Cadrenal Therapeutics is developing tecarfarin as a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds, and deaths than warfarin. Tecarfarin received orphan drug designation for advanced heart failure (search) patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (search) patients with atrial fibrillation (search).
Quang X. Pham, CEO of Cadrenal Therapeutics, stated that increasing tecarfarin data visibility will help accelerate development as they plan for investigator outreach and patient recruitment for the tecarfarin trial. The company is also planning pivotal clinical trials and pursuing clinical and commercial partnerships to advance tecarfarin, including studying its use in patients with mechanical heart valves experiencing anticoagulation difficulties.